详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China, [2]Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, China, [3]Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China, [4]Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China, [5]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China, [6]Academician (Expert) Workstation of Sichuan Province, Luzhou, China, [7]Clinical Medical College, Southwest Medical University, Luzhou, China, [8]Department of Anesthesiology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China, [9]Department of Spinal Surgery, No.1 Orthopedics Hospital of Chengdu, Chengdu, China, [10]Department of Oncology, 363 Hospital, Chengdu, China

出处：

DOI：

ISSN：

关键词： programmed death-ligand 1 circulating tumor cells hepatocellular carcinoma programmed death 1 inhibitor radiotherapy antiangiogenic therapy

摘要：

A programmed death 1 (PD-1) inhibitor coupled with radiotherapy and antiangiogenic therapy is a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). We aimed to determine if circulating tumor cells (CTCs) positive for programmed death-ligand 1 (PD-L1) could be employed as a predictive biomarker in HCC patients receiving triple therapy.In this study, HCC patients received a PD-1 inhibitor in combination with intensity-modulated radiotherapy (IMRT) and antiangiogenic therapy. Following IMRT, the PD-1 inhibitor was administrated once every 3 weeks, while the antiangiogenic drug was given once a day. Treatment was continued until the disease progressed. Two mL of peripheral blood was collected at baseline, 1 month, and 3 months after treatment for CTC enrichment using the CytoSorter® system with a CytoSorter™ CTC PD-L1 Kit (Watson Biotech., China).A total of 47 HCC patients receiving the triple therapy were enrolled in this study. Patients with < 2 PD-L1+ CTCs at baseline had a higher objective response rate (ORR) and longer overall survival (OS) than those with ≥ 2 PD-L1+ CTCs (56.5% vs. 16.7%, p = 0.007; not reach vs. 10.8 months, p = 0.001, respectively). The count of PD-L1+ CTCs was found to be an independent predictive biomarker of OS. Furthermore, the objective response was more likely to be achieved in patients with a dynamic decrease in PD-L1+ CTC counts at 1 month after treatment.Our study demonstrated that PD-L1+ CTCs could be a predictive biomarker for HCC patients receiving PD-1 inhibitors in combination with IMRT and antiangiogenic therapy.Copyright © 2022 Su, Guo, He, Rao, Zhang, Yang, Huang, Gu, Xu, Liu, Wang, Chen, Wu, Hu, Zeng, Li, Tong, Li, Yang, Liu, Xu, Tan, Tang, Feng, Chen, Yang, Jin, Zhu, Li and Han.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China,

共同第一作者：

通讯作者：

通讯机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China, [4]Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China, [5]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China, [6]Academician (Expert) Workstation of Sichuan Province, Luzhou, China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

文献详情

相关文献